CSRxP Statement on Secretary Azar’s Testimony in Front of Senate HELP Committee

Jun 12, 2018

“When the manufacturer-set price of a drug starts out high, the price of that drug when it reaches patients will inevitably end up high.  No amount of finger pointing can change the fact that the root cause of this crisis is out-of-control list and launch prices set by Big Pharma.  

“Fundamentally, the problem is the price, and so we are encouraged by Secretary Azar’s focus on changing the incentives that lead to those skyrocketing list and launch prices.  We will continue to work with the Administration and Congress to enact policies, like the bipartisan CREATES Act, that will end Big Pharma’s anticompetitive gaming and achieve our shared goal of lower prescription drug prices for all Americans.”